PUBLISHER: The Business Research Company | PRODUCT CODE: 1668474
PUBLISHER: The Business Research Company | PRODUCT CODE: 1668474
Organ transplant immunosuppressant drugs are crucial medications employed to curb the immune response in transplant recipients, mitigating the risk of rejection against the transplanted organ.
These drugs primarily fall into several classes calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, steroids, and other miscellaneous classes. Calcineurin, an enzyme pivotal in T-cell activation, prompts the immune system to attack transplanted organs. Calcineurin inhibitors serve to prevent such rejection reactions in patients undergoing organ transplantation. These drugs find extensive use in heart, kidney, liver, lung, pancreas, and other organ transplants, and they are typically dispensed through hospital pharmacies, retail outlets, and online pharmacy platforms.
The organ transplant immunosuppressant drugs market research report is one of a series of new reports from The Business Research Company that provides organ transplant immunosuppressant drugs market statistics, including organ transplant immunosuppressant drugs industry global market size, regional shares, competitors with an organ transplant immunosuppressant drugs market share, detailed organ transplant immunosuppressant drugs market segments, market trends and opportunities, and any further data you may need to thrive in the organ transplant immunosuppressant drugs industry. This organ transplant immunosuppressant drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The organ transplant immunosuppressant drugs market size has grown steadily in recent years. It will grow from$5.35 billion in 2024 to $5.52 billion in 2025 at a compound annual growth rate (CAGR) of 3.2%. The growth in the historic period can be attributed to increased transplant procedures, improved healthcare infrastructure, research and development, a global aging population, and increasing awareness
The organ transplant immunosuppressant drugs market size is expected to see steady growth in the next few years. It will grow to $6.61 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to emerging therapies, rising incidence of organ failures, personalized medicine, global health initiatives, and international collaboration. Major trends in the forecast period include technological innovations, technological advancements, cost containment strategies, market consolidation and partnerships, and increasing organ transplants.
The growing demand for organ transplantation is expected to enhance the organ transplant immunosuppressant drugs market. Organ transplantation involves surgically replacing a diseased or damaged organ in a person's body with a healthy organ from a donor. This life-saving procedure is crucial for replacing failed organs, and immunosuppressant drugs play a vital role in preventing the rejection of transplanted organs, which can result in organ failure. The availability and effectiveness of these drugs are critical to the success of transplantation. For example, in 2023, the Organ Procurement and Transplantation Network (OPTN), a U.S.-based public-private partnership, reported that approximately 16,335 individuals donated one or more organs after their passing. This marks the first year with over 15,000 deceased donors, reflecting a 9.6% increase from 2022. Thus, the rising demand for organ transplantation is driving growth in the organ transplant immunosuppressant drugs market.
The expanding geriatric population is projected to fuel the growth of the organ transplant immunosuppressant drugs market. Immunosuppressants are crucial for elderly transplant recipients, necessitating tailored drug regimens to prevent rejection while mitigating potential adverse effects and drug interactions. By 2030, the World Health Organization estimates that 1 in 6 people worldwide will be aged 60 or older, reaching 1.4 billion, doubling to 2.1 billion by 2050. This demographic shift underscores the market's growth driven by the expanding geriatric populace.
Product innovation is a significant trend in the organ transplant immunosuppressant drugs market. Major companies in this sector are concentrating on developing innovative solutions, such as combination therapies, to maintain their competitive edge. Combination therapy, which utilizes two or more immunosuppressant drugs, is becoming increasingly common as it can offer enhanced immunosuppression while minimizing the risk of side effects. For example, in March 2024, Johnson & Johnson, a U.S.-based pharmaceutical and biotechnology firm, received approval from the U.S. Food and Drug Administration (FDA) for OPSYNVI. This single-tablet combination is designed for the long-term management of pulmonary arterial hypertension (PAH) and includes tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, and macitentan, an endothelin receptor antagonist (ERA). OPSYNVI can be prescribed to patients with PAH who are either new to treatment or currently using an ERA, PDE5 inhibitor, or both. Additionally, patients who are taking consistent doses of macitentan 10 mg and tadalafil 40 mg (20 mg x 2) as separate tablets may be switched to OPSYNVI.
Market leaders in the organ transplant immunosuppressant drugs sector prioritize advanced drug solutions to augment their product portfolios and meet patient needs. Advanced medications aim to modulate the immune system in transplant recipients. For instance, in August 2023, Strides Pharma Science Ltd. secured USFDA approval for Cyclosporine Softgel Capsules USP (Modified), catering to kidney, liver, and heart transplant recipients. This approval reinforces Strides' position in the immunosuppressant market, complementing their existing offerings and enhancing patient care outcomes.
In January 2022, CareDx, Inc., a U.S.-based precision medicine company, acquired The Transplant Pharmacy for an undisclosed amount. This acquisition allows CareDx, Inc. to enhance its medication management portfolio, particularly in the area of organ transplantation. The Transplant Pharmacy specializes in providing transplant services at various locations, delivering personalized patient care that includes online patient portal services and a mobile app for medication management.
Major companies operating in the organ transplant immunosuppressant drugs market include Astellas Pharma Inc., F. Hoffmann-La Roche AG, Novartis AG, Accord Healthcare Limited, GlaxoSmithKline PLC, Pfizer Inc., Sanofi S.A., Alsachim a Shimadzu Group Company, Neovii Pharmaceuticals AG, Zydus Lifesciences Limited, Dr. Reddy's Laboratories Ltd., Lupin Limited, Mylan N.V., Strides Pharma Global Pte Ltd., Asahi Kasei Corporation, Bristol-Myers Squibb Company, Veloxis Pharmaceuticals A/S, Viatris Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Hansa Biopharma AB, Wockhardt Ltd, Glenmark Pharmaceuticals Ltd., Biocon Ltd., Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Intas Pharmaceuticals Limited, Alkem Laboratories Limited, Torrent Pharmaceuticals Limited
North America was the largest region in the organ transplant immunosuppressant drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global organ transplant immunosuppressant drugs market report during the forecast period. The regions covered in the organ transplant immunosuppressant drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the organ transplant immunosuppressant drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The organ transplant immunosuppressant drugs market consists of sales of drugs such asteroid-sparing immunosuppressants, prednisone, antineoplastics, monoclonal antibody drug, and immunosuppressive agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Organ Transplant Immunosuppressant Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on organ transplant immunosuppressant drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for organ transplant immunosuppressant drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The organ transplant immunosuppressant drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.